For CRC patients, mutation status of KRAS and NRAS in the primary tumor are currently routinely assessed after surgical resection by PCR-based methods to evaluate whether future therapeutic administration of EGFR inhibitors may be successful [6-8]. The gene discussed is KRAS; the disease is colorectal carcinoma.